Intravenous thrombolysis in acute ischemic stroke after dabigatran reversal with idarucizumab – a case report

Much excitement has been generated with the approval of idarucizumab, a humanized monoclonal antigen‐binding antibody fragment that is capable of reversing the anticoagulant activity of dabigatran. Here, we describe our initial experience of using tissue plasminogen activator (tPA) in an acute poste...

Descripción completa

Detalles Bibliográficos
Autores principales: Mutzenbach, Johannes Sebastian, Pikija, Slaven, Otto, Ferdinand, Halwachs, Ursula, Weymayr, Friedrich, Sellner, Johann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Case Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5099535/
https://www.ncbi.nlm.nih.gov/pubmed/27844035
http://dx.doi.org/10.1002/acn3.346

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5099535/
https://www.ncbi.nlm.nih.gov/pubmed/27844035
http://dx.doi.org/10.1002/acn3.346

Ejemplares similares